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Metabolic profile and insulin resistance in patients
with obstructive sleep apnea syndrome
Mustafa ŞAHİN1, Berrin BERÇİK İNAL1, Şahin ÖĞREDEN2, Özgür YİĞİT2,
Hale ARAL1, Güvenç GÜVENEN1

Aim: The following metabolic parameters were assessed in patients with obstructive sleep apnea syndrome (OSAS)
diagnosed by polysomnography (PSG): leptin, IFG (ımpaired fasting glucose), thyroid functions, thyroid autoantibodies,
lipid parameters, insulin levels, HOMA-IR index, CRP, obesity, and metabolic syndrome frequency.
Materials and methods: Three patient groups were defined based on apnea-hypoapnea index (AHI) levels (Group I: n:
11 male (M)/19 female (F); Group II: n: 19 M/10 F; Group III: n: 21 M/10 F) and 2 control groups (obese (n = 18 M/12
F) and normal (n = 12 M/18 F)) were included with comparable BMI value and age.
Results: The frequencies of metabolic syndrome were compared between patient groups, and no significant difference
was found, despite an increased frequency of metabolic syndrome from mild OSAS to severe OSAS. The following
significant differences were observed for insulin values: normal controls versus obese controls (P < 0.0001), normal
controls versus Group I (P = 0.014), normal controls versus Group II (P = 0.001), normal controls versus Group III (P <
0.0001), and Group I versus Group III (P = 0.026).
Conclusion: An increased frequency of metabolic syndrome and insulin resistance was found in OSAS patients. OSAS
patients with metabolic syndrome and insulin resistance are at an increased risk of diabetes mellitus and cardiovascular
diseases.
Key words: OSAS, Met-S, AHI, insulin resistance

Obstruktif uyku apne sendromlu hastalarda metabolik profil ve insülin direnci
Amaç: Bu çalışmada polisomnografi ile obstruktif uyku apne sendromu (OSAS) teşhisi konmuş hastaların aşağıda
belirtilen metabolik parametreleri değerlendirildi: leptin, bozulmuş açlık glukozu, tiroid fonksiyonları, tiroid
otoantikorları, lipid parametreleri, insülin seviyeleri, HOMA-IR indeks, obezite, ve metabolik sendrom sıklığı.
Yöntem ve gereç: Apne-hipoapne indeksi (AHI) temel alınarak 3 hasta grubu (Grup I: n: 11 Erkek (E)/ 19 Kadın (K);
Grup II: n: 19 E/10 K; Grup III: n: 21 E/10 K) ve vücut kitle indeksi (BMI) değeri ve yaş karşılaştırılmasını içeren iki
kontrol grubu (obez (n = 18 E/12 K) ve normal (n = 12E/18K)) tanımlandı.
Bulgular: Metabolik sendrom sıklığı hafif OSAS’dan ciddi OSAS’ a doğru artmasına rağmen hasta grupları arasında
anlamlı farklılık bulunamadı. İnsülin değerleri için farklılıklar gözlendi: normal kontrol obez kontrol karşısında (P <
0,0001): normal kontrol Grup I karşısında (P = 0,014); normal kontrol Grup II karşısında (P = 0,001); normal kontrol
Grup III karşısında ( P < 0,0001); Grup I Grup III karşısında (P < 0,026).
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Sonuç: OSAS’lı hastalarda artan metabolik sendrom sıklığı ve artan insülin direnci bulundu. Metabolik sendromlu ve
insülin direnci olan hastalarda diabetes mellitus ve kardiyovasküler hastalık riski artmıştır.
Anahtar sözcükler: OSAS, Met-S, AHI, insülin direnci

Introduction
Obstructive sleep apnea syndrome (OSAS) is
characterized by persistent and repetitive obstruction
of the upper airways during sleep. The obstructive
apnea represents the respiratory effort against a
partially or totally blocked airway and causes loud
snoring or arousal upon the restoration of airflow.
While snoring is the most frequent night symptom
of OSAS, excessive sleepiness is the most common
daytime symptom (1-3). Factors such as age, gender,
genetic factors, obesity (increased neck circumference
and thick/short neck), craniofacial abnormalities
(retrognathia, micrognathia), cigarette smoking, and
the use of alcohol or hypnotic drugs are associated
with an increased risk of OSAS. The male to female
ratio is 2.5:1 in the general population (4).
In this study, we explored the metabolic profile
and insulin resistance of OSAS patients attending the
sleep laboratory unit of our hospital in order to assess
possible relations between these conditions.
Materials and methods
This prospective study examines patients
who attended the outpatient clinic of the
Otorhinolaryngology Department of İstanbul
Education and Research Hospital between August
2008 and January 2009 with the complaint of
snoring. The Epworth Sleepiness Scale (ESS) was
completed by all patients with symptoms of OSAS
such as excessive snoring, morning fatigue, an
inability to sleep comfortably at night, and frequent
nocturnal urination. Patients with an ESS score of
9 or greater were referred to the sleep laboratory
for polysomnography (PSG) examinations with
an EMBLA S 7000 (USA) PSG device. For PSG
procedures, patients were asked to visit the sleep
laboratory in the evening hours. ECG, EOG, EEG,
EMG, and pulse oximetry were monitored for one
night of sleep via thoracoabdominal probes and
nasal cannula attached to the patient. Using the data
obtained from this observation, AHI, minimum
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oxygen saturation, mean oxygen saturation, and
oxygen desaturation index (ODI) levels were
estimated. According to AHI scores, patients were
classified as follows: simple snoring (AHI < 5), mild
OSAS (AHI = 5-15), moderate OSAS (AHI = 16-30),
and severe OSAS (AHI > 30).
Overall, 120 patients who underwent a PSG
and 60 healthy controls were included. Before the
study procedures, informed consent was obtained
from all patients. A total of 30 patients with a PSG
were excluded from the study because they met
the exclusion criteria, which included a history
of diabetes mellitus (DM), thyroid surgery and/
or medical treatment for thyroid disease, or use of
antidepressants. Patient groups were defined by
PSG results. Group I included patients with simple
snoring and mild OSAS (n = 30), Group II with
moderate OSAS (n = 29), and Group III with severe
OSAS (n = 29). The control group consisted of healthy
individuals with no signs of OSAS at ESS. In addition,
control subjects underwent an ENT examination
before the study and were required to demonstrate
no history of snoring or alcohol or cigarette use. The
2 control groups differed only with regard to BMI,
which was <25 and >30 in Groups I (n = 30) and II (n
= 30), respectively. The decision to include 2 separate
control groups was based on the high prevalence of
obesity among OSAS patients. Group I and Group
II were designated as normal controls and obese
controls, respectively.
The height (m), weight (kg), and waist
circumference (cm) of each subject was recorded
and BMI was calculated (kg/m2). Information on
alcohol and cigarette use, history of diabetes, use
of blood pressure lowering agents, thyroid disease,
and nocturia was obtained. In addition, symptoms
associated with OSAS were recorded.
Venous blood samples were collected between
0800 and 1000 following 8-10 h of fasting. The samples
were then placed in tubes containing clot activator
gel (BD Vacutainer® SSTTM II, BD Diagnostics,
Franklin Lakes, USA). The samples were kept at
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room temperature for 30 min before being subject to
centrifugation for 10 min at 1600 × g (4000 rpm).
Total cholesterol, LDL cholesterol, HDL
cholesterol, and triglycerides were determined
spectrophotometrically by an Abbott Aeroset
2.0 device. FT4, TSH, anti-TG, anti-TPO, and
insulin levels were determined via ECLIA
(Electrochemiluminescence Immunoassay) with a
Roche Hitachi E-170 device. For CRP estimations,
an Image 800 (Beckman Coulter) device was used
with a nephelometric method. Leptin levels were
determined by a Leptin kit (DRG International
Inc., USA) using the sandwich ELISA method.
Absorbance measurements for leptin were performed
in a microplate ELISA reader (GVD Reader-Washer)
at 450 nm.
Statistical analysis
SPSS 11.5 for Windows was used for statistical
analyses. The Kolmogorov-Smirnov test was used to
test the normality of continuous variables. Variables
with a Gaussian distribution (age, BMI, HDL,
waist circumference) were expressed as mean ±
SD and variables with a non-Gaussian distribution
(glucose, total cholesterol, triglycerides, low density
cholesterol, insulin, HOMA-IR, TSH, FT4, A-TPO,
CRP, leptin) were expressed as median value (in the
interquartile range). Between-group comparisons
for logarithmic or square root transformed variables
with a normal distribution were performed with a
one-way ANOVA analysis; Tukey and Tamhane’s
T2 tests were used for post-hoc analyses. Betweengroup comparisons of variables without a normal
distribution after transformation was done with
the Kruskal-Wallis test; for post-hoc comparisons,
the non-parametric Tukey-Kramer test was used.
For the comparison between the expected and
observed frequencies, chi-square tests were used
and Spearman’s correlation coefficient (rs) was used
for the correlation between variables. Dichotomous
dependent variables (patients and controls) for
independent variables (leptin, HOMA, CRP, age,
BMI) were analyzed by logistic regression analysis.
The odds ratios (OR) from the regression analysis
are presented with 95% confidence intervals (CI).
Statistical significance was set at a P value (2-tailed)
of less than 0.05.

Findings
This study was undertaken between August 2008
and January 2009 with 150 voluntary participants
at Istanbul Education and Research Hospital. The
demographic characteristics of patients are shown in
Table 1.
The distributions of continuous variables in all
5 groups were evaluated with the KolmogorovSmirnov test. Variables with a non-Gaussian group
distribution were expressed as median (25-75th
percentile), and those with a Gaussian distribution as
X ± SD (Table 2).
The frequencies of metabolic syndrome were
compared between patient groups using the chisquare test and no significant difference was found (P
= 0.331), despite an increased frequency of metabolic
syndrome from mild OSAS (69% (n = 20)) to severe
OSAS (74.2% (n = 23)). The prevalence in Group I
was determined to be 56.7% (n = 17).
The Pearson chi-square test did not show any
statistically significant difference between the 5
groups in terms of impaired fasting glucose (P =
0.102).
Tukey multiple comparisons following one-way
ANOVA analysis for the logarithmic glucose values
showed significant differences between normal
controls and Group II (P = 0.002) as well as those
found between normal controls and Group III (P =
0.009).
No significant between-group differences were
observed in TSH and FT4 levels (P values of 0.455
and 0.472, respectively) and in A-TG and A-TPO
positivity (P values of 0.531 and 0.082, respectively).
Tukey multiple comparisons after one-way
ANOVA analysis for logarithmic total cholesterol
values showed the following significant differences:
between normal controls and Group II (P = 0.002);
between normal controls and Group III (P < 0.001);
between obese controls and Group II (P = 0.005); and
between obese controls and Group III (P = 0.002).
The same comparison for triglyceride levels showed
the following significant differences: between normal
controls and Group I (P = 0.024); between normal
controls and Group II (P < 0.001); and between
normal controls and Group III (P < 0.0001). For HDL
cholesterol, the following differences were detected:
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Table 1. Demographic characteristics of patients.
Demographic variables

Group I
(mean ± SD)
(mild)

Group II
(mean ± SD)
(moderate)

Group III
(mean ± SD)
(severe)

Normal
controls
(mean ± SD)

Obese controls
(mean ± SD)

P value

11/19

19/10

21/10

12/18

18/12

= 0.035*

Age
(years)

50 ± 8

47 ± 12

49 ± 10

34 ± 10

34 ± 9

BMI
(kg/m2)

31.6 ± 5.5

31.8 ± 5.9

33.4 ± 4.8

22.6 ± 2.2

31.2 ± 3

< 0.0001**

Waist circumference
(cm)

104 ± 12

107 ± 12

111 ± 10

83 ± 11

104 ± 10

< 0.0001**

Smoking (%)

23.3%
(n = 7)

37.9%
(n = 11)

32.3%
(n = 10)

-

-

= 0.474*

Alcohol use (%)

16.7%
(n = 5)

27.6%
(n = 8)

32.3%
(n = 10)

-

-

= 0.360*

46.7%
(n = 14)

27.6%
(n = 8)

41.9%
(n = 13)

-

-

= 0.295*

Male/Female

Antihypertensive
medication use (%)

< 0.0001**

Age, BMI and waist circumference are presented as mean ± SD
*
P value obtained from chi-square test
**
P value obtained from one-way ANOVA

normal controls versus Group II (P = 0.037); and
normal controls versus Group III (P = 0.043). For
LDL cholesterol, the following differences were
observed with Tamhane’s T2 multiple-comparison:
normal controls versus Group II (P = 0.037); normal
controls versus Group III (P = 0.002); and obese
controls versus Group III (P = 0.005).
The following significant differences were
observed for insulin values with Tukey’s multiple
comparison tests after one-way ANOVA analysis:
normal controls versus obese controls (P < 0.0001);
normal controls versus Group I (P = 0.014); normal
controls versus Group II (P = 0.001); normal controls
versus Group III (P < 0.0001); and Group I versus
Group III (P = 0.026).
Tukey-Kramer multiple comparisons after
Kruskal-Wallis analysis for CRP revealed the
following differences between the groups: normal
controls versus Group II (P < 0.0001); normal
controls versus Group III (P < 0.0001); obese controls
versus Group II (P = 0.006); and obese controls versus
Group III (P < 0.0001).
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Tamhane’s T2 test after one-way ANOVA analysis
showed the following between-group differences for
HOMA-IR: normal controls versus obese controls
(P < 0.0001); normal controls versus Group I (P =
0.013); normal controls versus Group II (P < 0.001);
and normal controls versus Group III (P < 0.0001).
The effect of gender on leptin levels was explored
with univariate analysis of variance which showed
a significant interaction between gender and leptin
levels (P = 0.002). Thus, leptin levels in groups were
assessed separately for male and female participants.
Leptin levels are presented as median (25th-75th
percentile) and logarithmic transformation was done
before the comparison of the groups using one-way
ANOVA (Table 3).
Tamhane’s T2 test after one-way ANOVA analysis
showed the following significant differences for
leptin levels for male participants: normal controls
versus obese controls (P = 0.009), normal controls
versus Group I (P < 0.0001), normal controls versus
Group II (P < 0.0001), and normal controls versus
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Table 2. Biochemical profile of the groups.
Biochemical
variables

Group I*

Group II**

Group III***

Normal
Controls ¶

Obese Controls ¶¶

P value

Glucose (mg/dL)

96.5
(92.8-101)

98
(93-113)

97
(91-110)

89.5
(84.2-96)

97.5
(91.5-105.3)

= 0.003

Total cholesterol
(mg/dL)

216.5
(188.8-235.2)

228
(195.5-257)

217
(207-251)

174.5*
(160-200.5)

180
(151-230.5)

< 0.0001

160.5
(101-204.8)

169
(133-211.5)

189
(140-221)

92
(74-149)

131
(99.8-174)

< 0.0001

LDL cholesterol
(mg/dL)

143.5
(122.5-156.3)

147
(123.5-179)

140
(132-170)

107
(95-139)

115.5
(88.4-154)

< 0.0001

HDL cholesterol
(mg/dL)

42.1 ± 9.9

38.9 ± 8.7

39.1 ± 9.6

46 ± 11.1

39.2 ± 9.3

= 0.018

Insulin
(μU/mL)

12.5
(8.8-17.3)

12.7
(8.6-22.8)

18.24
(15.04-22.09)

7.66
(6.24-10.32

16.9
(9.3-20.8)

< 0.0001

HOMA-IR

2.8
(1.9-4.5)

3.2
(2.2-5.7)

4.6
(3-5.6)

1.63
(1.36-2.46)

3.8
(2.1-5.5)

< 0.0001

TSH
(mIU/L)

1.84
(1.01-2.54)

1.57
(1.13-2.69)

1.56
(1.13-2.21)

2.32
(1.25-3.75)

1.75
(1.31-2.2)

= 0.455

FT4 (ng/dL)

1.17 ± 0.15

1.22 ± 0.14

1.16 ± 0.16

1.22 ± 0.16

1.20 ± 0.17

= 0.472

10%
(n = 3)
13.3%
(n = 4)

3.4%
(n = 1)

16.1%
(n = 5)

6.7%
(n = 2)

10%
(n = 2)

= 0.531

10.3%
(n = 3)

16.5%
(n = 5)

10%
(n = 3)

6.7%
(n = 3)

= 0.0816

Triglyceride
(mg/dL)

Positive A-TG
(IU/mL) (%)
Positive A-TPO
(IU/mL) (%)
CRP
(mg/dL)

0.42
(0.17-0.71)

0.43
(0.26-0.78)

0.6
(0.26-0.94)

0.1
(0.1-0.19)

0.28
(0.15-0.35)

< 0.0001

Leptin
(ng/mL)

47.4
(17.7-144.9)

22.1
(9.3-52.9)

35.98
(10.17-85.61)

7.1
(2.8-13.7)

16.8
(8.1-30.1)

< 0.0001

HDL cholesterol and FT4 data are presented as mean ± SD. Glucose, total cholesterol, triglyceride, LDL cholesterol, TSH, CRP, leptin,
and HOMA data are presented as median (25th-75th percentile).
The Kruskal-Wallis test was used for the comparison of groups with regard to glucose and TSH levels.
For insulin, total cholesterol, triglyceride, LDL cholesterol, and leptin data, logarithmic transformation was done and groups were
compared using one-way ANOVA.
Square-root transformation was done for HOMA-IR data before one-way ANOVA.
The chi-square test was used to compare the groups with regard to the prevalence of positive results for A-TG and A-TPO. The KruskalWallis test was used to compare the groups for CRP levels.
Glucose:¶-**: P = 0.002; ¶-***: P = 0.009
Total cholesterol: ¶-**:P = 0.002; ¶-***: P < 0.001; ¶¶-**:P = 0.005; ¶¶-***:P = 0.002
Triglyceride: ¶ -*: P = 0.024; ¶-**: P < 0.001; ¶-***: P < 0.0001
LDL: ¶-**: P = 0.037; ¶-***: P = 0.002; ¶¶-***: P = 0.005
HDL: ¶-**: P = 0.037; ¶-***: P = 0.048
Insulin: ¶-¶¶: P < 0.0001; ¶-*: P = 0.014; ¶-**: P = 0.001; ¶-***: P < 0.0001; *-***: P = 0.026
HOMA-IR: ¶-¶¶: P < 0.0001; ¶-*: P = 0.013; ¶-**: P < 0.001; ¶-*** :P < 0.0001
CRP: ¶-**: P < 0.0001; ¶-***: P < 0.0001; ¶¶-**: P = 0.006; ¶¶-***: P < 0.0001
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Table 3. Leptin levels of the groups.

Leptin

Group I*

Group II**

GroupIII***

Normal
controls ¶

Obese controls
¶¶

P value

Male
n = 81

16.6
(10.3-25.1)

10.5
(6.9-30.4)

16.9
(8.5-37.6)

2.6
(2.0-3.9)

9.1
(5.1-13.3)

P < 0.0001

Female
n = 69

68.5
(45.7-180.6)

56.3
(45.0-122.5)

171.1
(83.5-259.6)

11.6
(7.6-19.7)

32.7
(27.2-39.3)

P < 0.0001

Males:
¶-¶¶:P = 0.009; ¶-*:P < 0.0001; ¶-**:P < 0.0001; ¶-***:P < 0.0001
Females:
¶-¶¶:P < 0.0001; ¶-*:P < 0.0001; ¶-*:P = 0.002; ¶-***:P < 0.001; ¶¶-***:P = 0.003

Group III (P < 0.0001). For female participants these
differences were as follows: normal controls versus
obese controls (P < 0.0001), normal controls versus
Group I (P < 0.0001), normal controls versus Group
II (P = 0.002), normal controls versus Group III (P
< 0.0001), and obese controls versus Group III (P =
0.003).
There was a moderately positive correlation
between HOMA and CRP, BMI and HOMA, and
BMI and CRP in the normal control group, while
no correlations were observed between HOMA
and leptin or CRP and leptin. In obese controls,
there was a moderately positive correlation between
HOMA and CRP, and BMI and HOMA, a strong
positive correlation between BMI and CRP, and a
weak positive correlation between HOMA and leptin
levels, with no correlation between CRP and leptin.
In the patient group, a moderate positive correlation

was observed between CRP and leptin, a strong
positive correlation was discovered between BMI
and HOMA, BMI and leptin, and BMI and CRP, and
weak correlations were found between HOMA and
leptin and HOMA and CRP (Table 4).
Two separate models were developed for logistic
regression analysis in which the patient group (n =
90) and normal controls (n = 30) were incorporated
as dependent variables and leptin, HOMA, CRP,
gender, age, and BMI as independent variables (Table
5).
Model 1: x = -2.37 + 0.61(leptin) + 0.63(HOMA)
+ 1.66(CRP)
Model 2: x = -28.5 + 0.11 (leptin) – 0.3 (HOMA)
-1.15 (CRP) + 0.082 (age) + 0.95 (BMI) + 1.37
(gender)
(x < 0: patient ; x > 0: normal control)

Table 4. Correlations between HOMA, CRP, leptin, and BMI in the groups.
Normal controls
(n = 30)

Obese controls
(n = 30)

Patient groups
(n = 90)

HOMA-Leptin

rs= 0.107 (P = 0.574)

rs= 0.218 (P = 0.247)

rs= 0.251 (P = 0.017)

HOMA-CRP

rs= 0.507 (P = 0.04)

rs= 0.365 (P = 0.048)

rs= 0.217 (P = 0.040)

CRP-Leptin

rs= 0.056 (P = 0.767)

rs= 0.121 (P = 0.525)

rs= 0.450 (P < 0.0001)

BMI-HOMA

rs= 0.482 (P = 0.007)

rs= 0.491 (P = 0.006)

rs= 0.551 (P < 0.0001)

BMI-Leptin

rs= -0.279 (P = 0.135)

rs= -0.047 (P = 0.805)

rs= 0.670 (P < 0.0001)

BMI-CRP

rs= 0.412 (P = 0.024)

rs= 0.558 (P < 0.001)

rs= 0.522 (P < 0.0001)

rs : Spearman correlation coefficient
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Table 5. Logistic regression analysis for Model 2.
Variable

β

SE

OR (95% CI)

P value

Constant value

-28.5

8.1

0.0001

P < 0.0001

Leptin

0.11

0.07

1.12 (0.97-1.29)

P = 0.116

HOMA

-0.3

0.4

0.7 (0.3-1.5)

P = 0.364

CRP

-1.15

1.4

0.3 (0.02-4.9)

P = 0.41

Age

0.082

0.049

1.08 (0.98-1.19)

P = 0.093

BMI

0.95

0.34

2.6 (1.32-5.1)

P = 0.005

Gender

1.37

1.74

3.94 (0.13-118.9)

P = 0.43

β: regression coefficient
SE: standard error
OR: odds ratio
95% CI: 95% confidence interval

The frequency of metabolic syndrome in patient
groups is shown in Figure 1.
The frequency of impaired glucose tolerance
(IGT) in the study groups is shown in Figure 2.

.8

Metabolic Syndrome Frequency

In Model 1, both leptin (P = 0.031) and HOMA (P
= 0.012) had significant effects on the categorization
of the patient group, while only BMI showed a
significant effect on this parameter (OR: 2.6 [1.325.1]; P = 0.005) in Model II, where age, BMI, and
gender were also included. Leptin and HOMA
emerged as BMI-dependent variables.

.7

.6

Discussion
OSAS is associated with a number of co-morbid
conditions, particularly with endocrinological
disturbances. For instance, 1.2% to 11% of
patients with OSAS have been reported to have
hypothyroidism (5-7).
In a study by Winkelman et al. involving 255
patients, hypothyroidism occurred at an incidence
of 1.6% and 2.9% in subjects with clinical sleep
disorder and in subjects with a diagnosis of OSAS,
respectively. In that study, the need for the evaluation
of thyroid functions in high-risk OSAS patients

.5
Group I

Group II

Group III

Figure 1. The frequency of metabolic syndrome in patient
groups.

(>60 years of age, female gender) with clinical signs
of hypothyroidism was emphasized (7). Skjodt et
al. reported newly diagnosed hypothyroidism in
1.5% of PSG patients and in 2.4% of patients with
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interaction was also reported for the development of
OSAS and obesity. The adverse effect of inadequate
nocturnal sleep on daytime physical activity was also
reported to play an important role in the progression
of obesity in OSAS (9).

.6

IFG - frequency

.5

.4

.3

.2

.1
Normal Control

Group I

Obese Control

Group III
Group II

Figure 2. The frequency of impaired glucose tolerance (IGT) in
the study groups.

suspected OSAS, proposing that routine screening
for hypothyroidism may provide cost savings by
eliminating the need for unnecessary investigations
for sleep disorders such as “primary sleep apnea”
(8). Lin et al. found hypothyroidism in 3.1% of 65
patients with OSAS, recommending routine use of
thyroid function tests in all OSAS patients; however,
these authors considered routine PSG unnecessary
in patients with hypothyroidism (5). Popovici et
al. detected hypothyroidism in 11% of 53 patients
with suspected OSAS, pointing out the common
co-existence of these 2 conditions (6). In our study,
a clinical diagnosis of hypothyroidism was made
with a TSH > 4.2 μIU/mL and FT4 < 0.93 ng/dL.
Using these cut-off values, 3 patients (3.3%), 2 of
whom had severe OSAS, were diagnosed as having
hypothyroidism. Our results are comparable to
previous reports.
In a study by Wolk et al., the association between
obesity and OSAS was evaluated, reporting obesity
in 70% of OSAS patients, and OSAS in 40% of obese
subjects. In addition, a 10% increase in body weight
was reported to increase the risk of sleep apnea by
an order of 6, while a 10% decrease was reported to
decrease AHI by 26%. A mutual and multifactorial
450

In our study, similar to previous reports, obesity
(BMI > 30 kg/m2) was present in 58 patients (64%),
confirming the strong association between OSAS
and obesity once more. In addition, hypertension
was found to be significantly associated with OSAS
in a variety of studies. In line with these observations,
39% of our OSAS patients (n = 35) were on
antihypertensives. The first major study involving
7511 patients was carried out in 1985 showing a 1.94and 3.13-fold increase in hypertension incidence
in snoring men and women, respectively (10). At
present, approximately 60% of OSAS patients are
estimated to be hypertensive, and the severity of
hypertension increases with the level of AHI (11).
An association between CRP and OSAS was shown
in a variety of studies and both adipose tissue and
obesity are known to play a role in the appearance of
low-grade inflammation (12). Increased CRP levels
represent an important risk factor for atherosclerosis,
cardiovascular diseases, and cerebrovascular
mortality. Recent studies also show an association
between increased waist to hip ratio, increased BMI,
and CRP (13). In addition, increased CRP levels were
reported in OSAS patients and levels were shown to
decrease upon CPAP treatment (14). In a study by
Guilleminault et al., no association between OSAS
and CRP was observed in less obese patients, while
only BMI was shown to be associated with CRP (15).
Shamsuzzaman et al. found increased CRP levels in
22 newly diagnosed OSAS patients compared to 20
healthy age- and BMI-matched controls (16).
In our study, CRP levels of OSAS patients were
significantly higher compared to normal and obese
controls. In addition, a strong positive correlation
was found between BMI and CRP, similar to the
findings of previous studies. Obesity is a central
component of other metabolic syndrome features
such as increased waist circumference, hypertension,
and hyperinsulinemia and it plays key role in the
development of diabetes. The risk of diabetes mellitus
in OSAS should also be borne in mind since these
components are frequently found in these patients.
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Marshall et al. found a diabetes prevalence of 4.7%
in a group of patients without apnea compared to
17.7% in those with severe apnea, corresponding to
an estimated odds ratio (OR) of 4.37. The incidence
of diabetes in a 4-year period was 2.2% in those
without apnea, and 20% in those with severe apnea
(OR: 11.2). Another prospective study by Reichmuth
et al. found an OR of 4.06 for patients with AHI >
15 compared to those with an AHI < 5 (17). These
findings suggest that apnea may play an important
role in the development of DM. In France, Meslier
et al. found an increased incidence of type 2 DM
and IGT among patients with OSAS compared to
the general population (30.1% and 20% increase,
respectively). In that country, the incidence of type 2
DM is between 3.5% and 8.6% for those between 45
and 74 years of age (18).
Higher BMI and waist circumference
measurements and higher levels of triglyceride,
total cholesterol, and LDL cholesterol among patient
groups compared to controls (i.e. presence of risk
indicators for the development of DM) together with
the association of AHI with increased prevalence of
impaired fasting glucose suggests a tendency towards
the development of diabetes mellitus in OSAS
patients. Thus, the findings of the study, particularly
the higher prevalence of impaired fasting glucose
in OSAS patients, underline the need for OGTT
screening in these patients.
In a case-control study by Coughlin et al.,
the presence of metabolic syndrome criteria was
examined in OSAS patients. An independent
relation was found for 61 patients with AHI > 15 and
for 43 patients with AHI < 5 and the odds ratio for
metabolic syndrome was 9.1 for OSAS patients. An
independent relation was also found between OSAS
and several other criteria, including systolic and
diastolic blood pressure, fasting insulin, triglyceride,
HDL cholesterol, and total cholesterol levels (19). In
a retrospective study by Parish et al., OSAS patients
had a higher prevalence of metabolic syndrome
compared to subjects without the condition (60%
versus 40%) (20).
In this study, there was an increase in the
prevalence of metabolic syndrome with increasing
OSAS severity: 56.6%, 69%, and 74.2% in patients
with mild, moderate, and severe OSAS, respectively.

When all OSAS patients were considered, the
frequency of metabolic syndrome was 67%. There is
a remarkable difference between the frequencies of
metabolic syndrome among OSAS patients and that of
the general population, clearly suggesting a tendency
towards diabetes and cardiovascular disease. The
higher prevalence of metabolic syndrome among
patients with OSAS indicates that these patients
should also be evaluated for the risk of diabetes and
cardiovascular disease.
Hyperglycemia and insulin resistance play
key roles in metabolic syndrome. Tkacova et al.
estimated insulin resistance in 98 patients with
or without OSAS using HOMA-IR formula. The
results of 28 patients without OSAS, 39 patients with
moderate OSAS, and 21 patients with severe OSAS
were compared. Fasting insulin levels and HOMAIR values were significantly higher in relation to the
increasing severity of the disease. Insulin resistance
was present in 33%, 44%, and 74% of subjects without
OSAS, with moderate OSAS, and with severe OSAS,
respectively. In addition, study subject’s apneahypopnea index was moderately positively correlated
with fasting insulin and HOMA-IR levels (r = 0.484
and r = 0.546, respectively). In that study, the 10-year
cardiovascular disease (CVD) risks of the patients
were also estimated using NCEP ATP III criteria;
a cardiovascular disease risk greater than 10% was
estimated in 21% of patients without OSAS, whereas
corresponding figures were 28% and 65% for patients
with moderate and severe OSAS, respectively. The
odds of having a CVD risk > 10% was 8 times higher
among patients with severe OSAS compared to
those patients who did not suffer from the condition
(odds ratio: 8.36) (21). Ip et al. examined the insulin
resistance of 185 OSAS patients with AHI > 5 using
the HOMA model and found an increase in insulin
resistance with age and obesity. In that study, a
multiple linear regression analysis was performed and
obesity emerged as the main causal factor for insulin
resistance (22). A study by Vgontzas et al. examined
14 obese patients with OSAS and 11 obese patients
without OSAS (age- and BMI-matched) for insulin
resistance and found higher levels of fasting blood
glucose and fasting insulin in patients with OSAS
compared to patients without this condition (23).
Brooks et al. demonstrated that insulin sensitivity
in obese diabetic patients with OSAS improved with
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4-month CPAP treatment (24). On the other hand,
Smurra et al. failed to demonstrate such a favorable
effect of CPAP on insulin resistance (25). In this
study, insulin levels of all groups were significantly
different when compared to normal controls. In
addition, the difference between obese controls and
normal controls with regard to insulin levels may
indicate that obesity is a causal factor for insulin
resistance, a theory which may also be supported
by the lack of any difference between obese controls
and other patient groups. In other words, although
insulin resistance increased along with increased
severity of the disease among patient groups, it
was significantly higher than normal controls. The
presence of insulin resistance in OSAS was in line
with previous studies. The high positive correlation
between BMI and HOMA-IR that we found among
the patient groups may be helpful in explaining the
role of obesity in insulin resistance. In addition, we
performed a correlation analysis to investigate a
possible increase in inflammation due to obesity and
found a high positive correlation between BMI and
CRP. On the other hand, in the patient group, we
found that the relation between inflammation and
insulin resistance offered a weak positive correlation
between CRP and HOMA-IR.
The high incidence of obesity among patients with
OSAS prompted the investigation of leptin, which is
secreted by adipose tissue and known to have a role in
nutrition and energy metabolism. In addition to this,
hyperleptinemia appears to lead to hypertension by
increasing extracellular sodium through sympathetic
nervous system activation and renal effects (26). The
increased levels of leptin with inflammation and the
role of obesity as a causal factor for inflammation
indicate a strong interaction between these 3 factors
(27). Leptin levels of OSAS patients were found to
be higher compared to those of the matched obese
control groups; the mechanism behind this is still
unknown, however. A decrease in leptin levels with
CPAP treatment suggests that leptin may interfere
with respiration. In addition, the correlation between
insulin resistance and leptin in patients with OSAS
needs to be explained. The use of a CPAP device, the
most effective treatment of OSAS, has been shown to
decrease leptin levels and improve insulin resistance
(28). This study demonstrated that CPAP treatment
has the potential to decrease cardiovascular disease
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risk by improving insulin resistance and leptin
levels. Impaired leptin receptors may explain the
development of obesity and increased tendency to
OSAS owing to the effects on food intake and energy
consumption (29). In a study by Sanner et al., 86
OSAS patients underwent polysomnography and
received 6-month CPAP treatment; however, serum
leptin levels were unchanged (30). Vgantzas et al.
found higher leptin levels among male OSAS patients
compared to BMI- and age-matched controls (23).
Kapsimalis et al. studied 67 male OSAS patients and
found increasing leptin levels with increased AHI
(31). Chin et al. demonstrated a decrease in serum
leptin levels in 22 OSAS patients on a similar diet
after 3 to 4 days of CPAP treatment, without any
change in body weight (32). Although controversial
results have been obtained from studies examining
the relationship between leptin and OSAS, the effect
of obesity on leptin levels is primarily emphasized.
Since leptin levels are known to be higher among
females, we examined our patients with regard to
gender. Leptin levels of our male patients in the
normal control group were significantly different
when compared to other patient groups and obese
controls. The lack of any significant difference
between obese controls and patient groups may
indicate that the increased leptin levels may be BMIdependent, which is further supported by the strong
positive correlation between BMI and leptin levels.
These results are consistent with previous studies.
Leptin levels of female participants were higher than
those of their male counterparts, which is also parallel
with the findings of previous studies. Similarly,
leptin levels of females were significantly higher in
all patient groups and obese controls compared to
normal controls. Since leptin originates from adipose
tissue, this was an expected result. Another important
finding was the significant difference between obese
controls and patients with severe OSAS, suggesting
that the relation between OSAS and leptin among
females may not be solely caused by a high BMI. As
demonstrated in previous studies, a decrease in AHI
together with a reduction in leptin levels despite no
concomitant change in BMI suggests an independent
relation between leptin and OSAS. We believe that
CPAP treatment may correct high leptin levels,
which is a pathophysiological consequence of OSAS,
independent of obesity.
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In conclusion, the relationship relation between
obesity and OSAS and its potential role in OSAS
pathogenesis have been emphasized in all previous
studies. Correction of obesity appears to be associated
with improvements in all pathological conditions and
parameters associated with OSAS such as metabolic
syndrome, insulin resistance, cardiovascular disease
risk, hypertension prevalence, and leptin levels.
Rather than being a simple social problem,
snoring should be regarded as a serious health
issue; all patients should be evaluated by both ESS
and physical examination for the presence of OSAS

and referred to a sleep laboratory where necessary.
Currently, the CPAP device is the most widely
accepted form of treatment for OSAS. The treatment
of obesity is also of particular importance in order
to decrease the risk of OSAS and metabolic disease.
The high prevalence of metabolic syndrome and
insulin resistance indicates a high risk of diabetes
and cardiovascular disease among patients with
OSAS. Thus, a multidisciplinary approach with the
contributions of cardiologists, endocrinologists,
psychiatrists, and dietitians would be most helpful in
the treatment of patients with OSAS.
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